DCM
XENE icon

Driehaus Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Driehaus Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267M Sell
4,418,557
-73,096
-2% -$4.06M 1.55% 4
2026
Q1 		$261M Sell
4,491,653
-47,038
-1% -$2.17M 1.92% 3
2025
Q4 		$203M Buy
4,538,691
+369,577
+9% +$15.5M 1.38% 5
2025
Q3 		$167M Sell
4,169,114
-166,534
-4% -$5.87M 1.2% 5
2025
Q2 		$136M Sell
4,335,648
-249,211
-5% -$8.13M 1.09% 9
2025
Q1 		$154M Buy
4,584,859
+64,264
+1% +$2.44M 1.48% 4
2024
Q4 		$177M Sell
4,520,595
-75,126
-2% -$3.11M 1.46% 4
2024
Q3 		$181M Buy
4,595,721
+176,249
+4% +$7.11M 1.55% 7
2024
Q2 		$172M Buy
4,419,472
+97,732
+2% +$3.91M 1.67% 6
2024
Q1 		$186M Sell
4,321,740
-23,440
-0.5% -$1.08M 1.85% 4
2023
Q4 		$200M Sell
4,345,180
-167,825
-4% -$5.93M 2.41% 2
2023
Q3 		$154M Sell
4,513,005
-247,848
-5% -$9.27M 2% 3
2023
Q2 		$183M Buy
4,760,853
+105,928
+2% +$4.21M 2.31% 2
2023
Q1 		$167M Sell
4,654,925
-26,872
-0.6% -$993K 2.34% 2
2022
Q4 		$185M Buy
4,681,797
+177,777
+4% +$6.47M 2.75% 2
2022
Q3 		$163M Buy
4,504,020
+112,982
+3% +$4.06M 2.46% 2
2022
Q2 		$134M Buy
4,391,038
+1,090,611
+33% +$33M 2.16% 2
2022
Q1 		$101M Buy
3,300,427
+177,198
+6% +$5.3M 1.24% 7
2021
Q4 		$97.6M Buy
3,123,229
+1,611,686
+107% +$48.2M 1% 16
2021
Q3 		$23.1M Buy
1,511,543
+566,408
+60% +$9.84M 0.27% 116
2021
Q2 		$17.6M Buy
945,135
+173,725
+23% +$3.2M 0.23% 143
2021
Q1 		$13.8M Buy
771,410
+325,966
+73% +$5.52M 0.2% 152
2020
Q4 		$6.85M Sell
445,444
-5,863
-1% -$68.6K 0.11% 216
2020
Q3 		$5M Sell
451,307
-12,926
-3% -$152K 0.1% 206
2020
Q2 		$5.82M Buy
464,233
+1,901
+0.4% +$24.2K 0.14% 174
2020
Q1 		$5.24M Buy
+462,332
New +$6.58M 0.18% 141

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Driehaus Capital Management's XENE Position: Q2 2026 in Review

Driehaus Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 1.6% in Q2 2026, selling an estimated $4.06M and leaving 4,418,557 shares worth $267M. The position accounts for 1.55% of the portfolio, ranked #4.

Driehaus Capital Management first reported a position in XENE in Q1 2020 and has held it in 26 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Driehaus Capital Management held 4,418,557 shares of Xenon Pharmaceuticals worth $267M as of Q2 2026.
  • Driehaus Capital Management sold 73,096 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.06M.
  • Xenon Pharmaceuticals made up 1.55% of Driehaus Capital Management's portfolio in Q2 2026, its #4 holding.
  • Driehaus Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.